Razumab 2.3mg

Razumab 2.3mg injection contains the active ingredient Ranibizumab. It functions as an anti-neovascularisation agent within the category of medications known as vascular endothelial growth factor A (VEGF-A) antagonists. This injection is prescribed to adults for the treatment of various eye diseases that lead to vision impairment. It is specifically utilized for managing wet age-related macular degeneration (AMD), a chronic eye condition that results in the loss of central vision and can hinder activities such as reading, driving, or other daily tasks.

Additionally, Razumab 2.3mg injection is indicated for the treatment of myopic choroidal neovascularization (mCNV), a complication associated with nearsightedness where abnormal blood vessels develop at the back of the eye. It is also effective in treating macular edema following retinal vein occlusion, a condition characterized by the blockage of blood flow from the eye, which can cause blurred vision and potential vision loss. Furthermore, it is used to address diabetic macular edema, a diabetes-related eye condition that may result in vision loss, as well as diabetic retinopathy, which involves damage to the eyes due to diabetes.

Patients should avoid using Razumab 2.3mg injection if they are allergic to Ranibizumab or any other components of this medication. It is also contraindicated in individuals with infections in or around the eye, as well as those experiencing pain or redness in the eye. It is crucial to notify your doctor immediately if you experience symptoms such as eye pain or increased discomfort, worsening redness in the eye, blurred or diminished vision, a rise in the number of small particles in your vision, or heightened sensitivity to light. Additionally, inform your healthcare provider if you have a history of eye conditions or treatments, or if you have previously suffered a stroke before starting this treatment.